Vivet Therapeutics and Pfizer entered a manufacturing agreement under which Pfizer's Chapel Hill, NC facility supplied clinical material for the GATEWAY Phase 1/2 trial of VTX-801 (AAV gene therapy for Wilson disease). Builds on Pfizer's 2019 minority equity stake and exclusive option to acquire Vivet. Terms not disclosed.